Intervention Protocol

Anti-IL-17 monoclonal antibody for induction of remission in Crohn's disease

  1. Shaoheng Zhang1,
  2. Runhua Li1,
  3. Qing Qing2,
  4. Ting Zhang1,
  5. Youlian Zhou1,
  6. Ye Chen1,*,
  7. Yali Zhang1,
  8. Siheng Lin1,
  9. Yangyang Liu1

Editorial Group: Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Group

Published Online: 17 OCT 2012

DOI: 10.1002/14651858.CD010147


How to Cite

Zhang S, Li R, Qing Q, Zhang T, Zhou Y, Chen Y, Zhang Y, Lin S, Liu Y. Anti-IL-17 monoclonal antibody for induction of remission in Crohn's disease (Protocol). Cochrane Database of Systematic Reviews 2012, Issue 10. Art. No.: CD010147. DOI: 10.1002/14651858.CD010147.

Author Information

  1. 1

    Department of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangdong Provincial Key Laboratory of Gastroenterology, Guangzhou, Guangdong, China

  2. 2

    Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Department of Gastroenterology, Guangzhou, Guangdong, China

*Ye Chen, Guangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital, Southern Medical University, No.1838, Guangzhou North Avenue, Baiyun District, Guangzhou, Guangdong, 510515, China. yechen_fimmu@163.com. chenye2001@hotmail.com.

Publication History

  1. Publication Status: New
  2. Published Online: 17 OCT 2012

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

The primary objectives are to assess the efficacy and safety of IL-17 monoclonal antibody for induction of remission in Crohn's disease.